ionis pharmaceuticals inc. - IONS
IONS
Close Chg Chg %
28.68 -0.30 -1.05%
Closed Market
28.38
-0.30 (1.05%)
Volume: 1.52M
Last Updated:
Apr 15, 2025, 4:00 PM EDT
Company Overview: ionis pharmaceuticals inc. - IONS
IONS Key Data
| Open $28.62 | Day Range 28.16 - 28.97 |
| 52 Week Range 23.95 - 52.34 | Market Cap $4.44B |
| Shares Outstanding 158.97M | Public Float 154.59M |
| Beta 0.29 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$3.04 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 1.90M |
IONS Performance
| 1 Week | 1.72% | ||
| 1 Month | -13.90% | ||
| 3 Months | -9.70% | ||
| 1 Year | -30.24% | ||
| 5 Years | -48.47% |
IONS Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
27
Full Ratings ➔
About ionis pharmaceuticals inc. - IONS
Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli, and Brett P. Monia on January 10, 1989 and is headquartered in Carlsbad, CA.
IONS At a Glance
Ionis Pharmaceuticals, Inc.
2855 Gazelle Court
Carlsbad, California 92010
| Phone | 1-760-931-9200 | Revenue | 705.14M | |
| Industry | Pharmaceuticals: Major | Net Income | -453,897,000.00 | |
| Sector | Health Technology | Employees | 1,069 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
IONS Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 7.413 |
| Price to Book Ratio | 9.383 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -10.777 |
| Enterprise Value to Sales | 6.925 |
| Total Debt to Enterprise Value | 0.401 |
IONS Efficiency
| Revenue/Employee | 659,623.948 |
| Income Per Employee | -424,599.626 |
| Receivables Turnover | 7.649 |
| Total Asset Turnover | 0.235 |
IONS Liquidity
| Current Ratio | 8.471 |
| Quick Ratio | 8.431 |
| Cash Ratio | 7.445 |
IONS Profitability
| Gross Margin | 95.291 |
| Operating Margin | -67.374 |
| Pretax Margin | -65.245 |
| Net Margin | -64.37 |
| Return on Assets | -15.146 |
| Return on Equity | -93.104 |
| Return on Total Capital | -17.82 |
| Return on Invested Capital | -18.761 |
IONS Capital Structure
| Total Debt to Total Equity | 332.927 |
| Total Debt to Total Capital | 76.901 |
| Total Debt to Total Assets | 65.213 |
| Long-Term Debt to Equity | 331.35 |
| Long-Term Debt to Total Capital | 76.537 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Ionis Pharmaceuticals Inc. - IONS
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 810.46M | 587.37M | 787.65M | 705.14M | |
Sales Growth
| +11.13% | -27.53% | +34.10% | -10.48% | |
Cost of Goods Sold (COGS) incl D&A
| 30.40M | 36.22M | 31.63M | 33.20M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 19.56M | 22.11M | 22.50M | 21.99M | |
Depreciation
| 17.21M | 19.69M | 19.94M | 19.65M | |
Amortization of Intangibles
| 2.35M | 2.42M | 2.56M | 2.34M | |
COGS Growth
| +4.45% | +19.14% | -12.67% | +4.98% | |
Gross Income
| 780.05M | 551.15M | 756.02M | 671.93M | |
Gross Income Growth
| +11.41% | -29.35% | +37.17% | -11.12% | |
Gross Profit Margin
| +96.25% | +93.83% | +95.98% | +95.29% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 810.24M | 961.34M | 1.11B | 1.15B | |
Research & Development
| 643.45M | 833.15M | 899.63M | 901.53M | |
Other SG&A
| 166.79M | 128.19M | 210.12M | 245.48M | |
SGA Growth
| -7.11% | +18.65% | +15.44% | +3.36% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| (1.48M) | 7.33M | (11.49M) | 2.89M | |
EBIT after Unusual Expense
| (28.71M) | (417.52M) | (342.24M) | (477.97M) | |
Non Operating Income/Expense
| 8.91M | 167.66M | 89.74M | 108.35M | |
Non-Operating Interest Income
| 10.04M | 25.33M | 89.04M | 107.02M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 9.35M | 8.12M | 81.46M | 90.45M | |
Interest Expense Growth
| -79.22% | -13.12% | +902.92% | +11.04% | |
Gross Interest Expense
| 9.35M | 8.12M | 81.46M | 90.45M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (29.15M) | (257.99M) | (333.96M) | (460.07M) | |
Pretax Income Growth
| +82.86% | -785.09% | -29.45% | -37.76% | |
Pretax Margin
| -3.60% | -43.92% | -42.40% | -65.25% | |
Income Tax
| (551.00K) | 11.74M | 32.32M | (6.17M) | |
Income Tax - Current - Domestic
| (890.00K) | 11.65M | 32.17M | (6.34M) | |
Income Tax - Current - Foreign
| 339.00K | 86.00K | 147.00K | 169.00K | |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (28.60M) | (269.72M) | (366.29M) | (453.90M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (28.60M) | (269.72M) | (366.29M) | (453.90M) | |
Net Income Growth
| +93.67% | -843.18% | -35.80% | -23.92% | |
Net Margin Growth
| -3.53% | -45.92% | -46.50% | -64.37% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (28.60M) | (269.72M) | (366.29M) | (453.90M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (28.60M) | (269.72M) | (366.29M) | (453.90M) | |
EPS (Basic)
| -0.2028 | -1.9015 | -2.558 | -3.0358 | |
EPS (Basic) Growth
| +93.73% | -837.62% | -34.53% | -18.68% | |
Basic Shares Outstanding
| 141.02M | 141.85M | 143.19M | 149.51M | |
EPS (Diluted)
| -0.2028 | -1.9015 | -2.558 | -3.0358 | |
EPS (Diluted) Growth
| +93.73% | -837.62% | -34.53% | -18.68% | |
Diluted Shares Outstanding
| 141.02M | 141.85M | 143.19M | 149.51M | |
EBITDA
| (10.63M) | (388.09M) | (331.23M) | (453.09M) | |
EBITDA Growth
| +93.14% | -3,552.23% | +14.65% | -36.79% | |
EBITDA Margin
| -1.31% | -66.07% | -42.05% | -64.26% |
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 56.00 | |
| Number of Ratings | 27 | Current Quarters Estimate | -0.991 | |
| FY Report Date | 06 / 2025 | Current Year's Estimate | -3.817 | |
| Last Quarter’s Earnings | -1.04 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -3.04 | Next Fiscal Year Estimate | -3.001 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 15 | 14 | 19 | 20 |
| Mean Estimate | -0.99 | -0.88 | -3.82 | -3.00 |
| High Estimates | -0.80 | -0.68 | -3.26 | -2.11 |
| Low Estimate | -1.16 | -1.07 | -4.29 | -3.76 |
| Coefficient of Variance | -11.56 | -13.22 | -8.36 | -15.15 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 17 | 16 | 17 |
| OVERWEIGHT | 1 | 1 | 1 |
| HOLD | 8 | 8 | 6 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 1 | 1 | 1 |
| MEAN | Overweight | Overweight | Overweight |
SEC Filings for Ionis Pharmaceuticals Inc. - IONS
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Ionis Pharmaceuticals Inc. - IONS
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Mar 14, 2025 | Brett P. Monia Chief Executive Officer; Director | 180,980 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $32.32 per share | 5,849,273.60 |
| Feb 7, 2025 | Patrick R. O'Neil EVP CLO & General Counsel | 57,452 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $31.62 per share | 1,816,632.24 |
| Jul 18, 2024 | Joseph Loscalzo Director | 4,079 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jul 18, 2024 | Allene M. Diaz Director | 15,716 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $50.17 per share | 788,471.72 |
| Jul 18, 2024 | Spencer R. Berthelsen Director | 4,079 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jul 18, 2024 | Allene M. Diaz Director | 4,079 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jul 18, 2024 | Spencer R. Berthelsen Director | 151,934 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jul 18, 2024 | Joseph H. Wender Director | 4,079 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jul 18, 2024 | Joseph H. Wender Director | 132,756 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jul 18, 2024 | B. Lynne Parshall Director | 4,079 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jul 18, 2024 | B. Lynne Parshall Director | 87,265 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jul 18, 2024 | Joseph R. Klein Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jul 18, 2024 | Allene M. Diaz Director | 16,453 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $48.94 per share | 805,209.82 |
| Jul 18, 2024 | Allene M. Diaz Director | 17,353 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jul 18, 2024 | Joseph R. Klein Director | N/A | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $50 per share | 0.00 |
| Jul 18, 2024 | Joseph R. Klein Director | 12,000 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $24.42 per share | 293,040.00 |
| Jul 18, 2024 | Joan Elizabeth Herman Director | 4,079 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jul 18, 2024 | Joan Elizabeth Herman Director | 42,007 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jul 18, 2024 | Joseph Loscalzo Director | 45,759 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jul 4, 2024 | Michael R. Hayden Director | 10,111 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |